Display options
Cite
Jelvehgaran P, Alderliesten T, Georgiou G, et al. Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomed Opt Express. 2018;9(9):4196-4216doi: 10.1364/BOE.9.004196.
Jelvehgaran, P., Alderliesten, T., Georgiou, G., Meijer, S. L., Bloemen, P. R., Kodach, L. L., van Laarhoven, H. W. M., van Berge Henegouwen, M. I., Hulshof, M. C. C. M., Rasch, C. R. N., van Leeuwen, T. G., de Boer, J. F., de Bruin, M., & van Herk, M. (2018). Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomedical optics express, 9(9), 4196-4216. https://doi.org/10.1364/BOE.9.004196
Jelvehgaran, Pouya, et al. "Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study." Biomedical optics express vol. 9,9 (2018): 4196-4216. doi: https://doi.org/10.1364/BOE.9.004196
Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M. Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomed Opt Express. 2018 Aug 14;9(9):4196-4216. doi: 10.1364/BOE.9.004196. eCollection 2018 Sep 01. PMID: 30615728; PMCID: PMC6157785.
Copy Download .nbib Format: NLM
Share it on

Biomed Opt Express. 2018 Aug 14;9(9):4196-4216. doi: 10.1364/BOE.9.004196. eCollection 2018 Sep 01.

Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study.

Biomedical optics express

Pouya Jelvehgaran, Tanja Alderliesten, Giota Georgiou, Sybren L Meijer, Paul R Bloemen, Liudmila L Kodach, Hanneke W M van Laarhoven, Mark I van Berge Henegouwen, Maarten C C M Hulshof, Coen R N Rasch, Ton G van Leeuwen, Johannes F de Boer, Martijn de Bruin, Marcel van Herk

Affiliations

  1. Department of Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  2. Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  3. Institute for Laser Life and Biophotonics Amsterdam, Department of Physics and Astronomy, VU University Amsterdam, Amsterdam 1081 HV, The Netherlands.
  4. Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  5. Department of Medical Oncology, Amsterdam UMC and Cancer Center Amsterdam, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  6. Department of Surgery, Amsterdam UMC and Cancer Center Amsterdam, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  7. Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.
  8. Manchester Cancer Research Centre, Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PL, UK.

PMID: 30615728 PMCID: PMC6157785 DOI: 10.1364/BOE.9.004196

Abstract

Treatment of resectable esophageal cancer includes neoadjuvant chemo-radiation therapy (nCRT) followed by esophagectomy in operable patients. High-risk surgery may have been avoided in patients with a pathological complete response (pCR). We investigated the feasibility of optical coherence tomography (OCT) to detect residual cancer and radiation-induced fibrosis in 10 esophageal cancer patients that underwent nCRT followed by esophagectomy. We compared our OCT findings with histopathology. Overall, OCT was able to differentiate between healthy tissue, fibrotic tissue, and residual cancer with a sensitivity and specificity of 79% and 67%, respectively. Hence, OCT has the potential to add to the assessment of a pCR.

Keywords: (170.0170) Medical optics and biotechnology; (170.1610) Clinical applications; (170.2150) Endoscopic imaging

Conflict of interest statement

Dr. T. Alderliesten is involved in projects supported by Elekta. Prof. H.W.M van Laarhoven is involved in researches supported by Bayer B.V., Bristol-Myers Squibb, Celgene, Janssen & Janssen, Lilly, N

References

  1. Gastrointest Endosc. 2000 Apr;51(4 Pt 1):467-74 - PubMed
  2. Gastrointest Endosc. 2001 Aug;54(2):219-24 - PubMed
  3. N Engl J Med. 2002 Apr 11;346(15):1128-37 - PubMed
  4. Ann Thorac Surg. 2003 Jan;75(1):217-22; discussion 222 - PubMed
  5. Am J Surg. 2003 Jun;185(6):538-43 - PubMed
  6. Gut. 2004 Jul;53(7):925-30 - PubMed
  7. Phys Med Biol. 2005 Apr 7;50(7):1569-83 - PubMed
  8. J Clin Oncol. 2005 Apr 1;23(10):2310-7 - PubMed
  9. Clin Gastroenterol Hepatol. 2006 Jan;4(1):38-43 - PubMed
  10. Gastrointest Endosc. 2006 Jun;63(7):938-47 - PubMed
  11. Nat Med. 2006 Dec;12(12):1429-33 - PubMed
  12. J Clin Oncol. 2007 Apr 1;25(10):1160-8 - PubMed
  13. Br J Surg. 2007 Dec;94(12):1515-20 - PubMed
  14. Ann Thorac Surg. 2008 Feb;85(2):S751-6 - PubMed
  15. Opt Express. 2008 Feb 18;16(4):2469-85 - PubMed
  16. Clin Radiol. 2008 Jul;63(7):765-73 - PubMed
  17. Opt Express. 1997 Dec 22;1(13):432-40 - PubMed
  18. Science. 1991 Nov 22;254(5035):1178-81 - PubMed
  19. Gastrointest Endosc. 2010 May;71(6):899-906 - PubMed
  20. Ann Thorac Surg. 2010 Sep;90(3):936-42; discussion 942 - PubMed
  21. J Clin Oncol. 2010 Nov 1;28(31):4714-21 - PubMed
  22. World J Surg. 2011 Mar;35(3):608-16 - PubMed
  23. World J Surg. 2011 Aug;35(8):1853-60 - PubMed
  24. Eur J Surg Oncol. 2011 Sep;37(9):774-8 - PubMed
  25. Clin Oncol (R Coll Radiol). 2012 Mar;24(2):86-104 - PubMed
  26. N Engl J Med. 2012 May 31;366(22):2074-84 - PubMed
  27. J Biomed Opt. 2012 Jun;17(6):060501 - PubMed
  28. Gastrointest Endosc. 2012 Sep;76(3):548-55 - PubMed
  29. Biomed Opt Express. 2012 Oct 1;3(10):2600-10 - PubMed
  30. J Urol. 2013 Dec;190(6):2236-42 - PubMed
  31. Gastrointest Endosc. 2014 Jun;79(6):886-96 - PubMed
  32. Radiat Oncol. 2014 Aug 29;9:191 - PubMed
  33. Gastrointest Endosc. 2015;81(6):1346-54 - PubMed
  34. Dis Esophagus. 2016 Aug;29(6):505-12 - PubMed
  35. Gastrointest Endosc. 2015 Oct;82(4):631-40 - PubMed
  36. JMIR Res Protoc. 2015 Jun 29;4(2):e79 - PubMed
  37. Lancet Oncol. 2015 Sep;16(9):1090-1098 - PubMed
  38. Endoscopy. 2015 Sep;47(9):829-54 - PubMed
  39. PLoS One. 2015 Nov 03;10(11):e0133690 - PubMed
  40. BMC Cancer. 2017 Jun 14;17(1):413 - PubMed
  41. Surg Endosc. 2018 Jan;32(1):204-211 - PubMed
  42. Virchows Arch. 2018 Feb;472(2):175-186 - PubMed
  43. Med Phys. 2017 Dec;44(12):6570-6582 - PubMed
  44. J Biomed Opt. 2018 Apr;23(4):1-12 - PubMed
  45. Ann Surg. 1986 Feb;203(2):173-6 - PubMed
  46. Cancer. 1994 Jun 1;73(11):2680-6 - PubMed
  47. Science. 1997 Jun 27;276(5321):2037-9 - PubMed
  48. N Engl J Med. 1997 Jul 17;337(3):161-7 - PubMed
  49. Gastrointest Endosc. 1998 Jun;47(6):515-23 - PubMed

Publication Types